Neurocrine Biosciences Inc. (NBIX) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

NO DATA

Deutsche Bank has cut its price target for Neurocrine Biosciences to $165 from $190, citing a less optimistic earnings outlook and a tougher competitive landscape. The downgrade signals that the bank now views the company’s valuation as over‑extended relative to its near‑term fundamentals. Because the consensus target remains above $210, the market may interpret the cut as a warning that the upside is more limited than previously thought. Over the next 1–10 trading days, traders should watch for any earnings guidance that could confirm or refute the bank’s concerns, as well as any pipeline updates that might alter the competitive assessment. The price target reduction could also prompt a reassessment of valuation assumptions by other analysts, potentially leading to a broader re‑evaluation of the company’s growth prospects. Monitoring the company’s upcoming earnings release will be key to determining whether the earnings outlook truly warrants a lower target. Additionally, any new data on product development or regulatory milestones could shift the competitive narrative and influence the stock’s trajectory. Finally, keep an eye on market sentiment toward biotech valuations, as a broader sell‑off could amplify the impact of the target cut.

NBIX|Company Info

No Data Available

Sector

Industry

Exchange

Country

Website

Symbol

NBIX

Description

No description available for this symbol yet.

NBIX|Earnings Snapshot

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$2.72	-	-
Q3'25	$2.07	$2.17	+4.9%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$1.1B	-	-
Q3'25	-	$795M	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

NBIX Stock Snapshot

NBIX is currently trading at $153.11, giving Neurocrine Biosciences Inc. a market cap of 15.51B and a P/E ratio of 22.0. Today's range spans $152.00–$158.41, with shares opening at $153.84 and moving up $0.07 (0.0%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD).

Over the past year NBIX has traded between $122.14 and $186.12 - the current price is +25.4% off the 52-week low and -17.7% from the high. 38 analysts cover the stock with a Buy consensus and a mean 12-month target of $211.57 (range $165.00–$249.00), implying upside of +38.2%.

The technical picture for NBIX is mixed - score 55/100, HOLD, with the stock at $153.11 (in the middle of its 52-week range) and sentiment neutral at -/100. For a large-cap in the broader market with 15.51B in capitalization The current P/E ratio stands at 22.0., this is a fairly common pre-earnings or pre-macro-event posture. Annual range: $122.14–$186.12. Neutral signals at this size often resolve sharply once a catalyst provides directional conviction.

Portfolio construction in the broader market often uses large-cap names like NBIX as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 55/100 (HOLD) at $153.11 (in the middle of its 52-week range) and neutral sentiment (-/100) frame the position as a catalyst play within the $122.14–$186.12 annual range rather than a directional bet.

News Sentiment Analysis

Sentiment gathered from recent headlines

No data

Strong NegativeNeutralStrong Positive

NO DATA

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

4 articles

What did this article say?

Deutsche Bank reduced its price target for Neurocrine Biosciences (NBIX) from $190 to $165 while keeping a hold rating. The downgrade reflects concerns over the company’s earnings outlook and competitive landscape. NBIX’s current consensus target remains $210.27, indicating a broader market view that the stock may still have upside. The adjustment may pressure the stock price and signal caution to investors. Traders should monitor upcoming earnings releases and any updates on the company’s pipeline. The change also highlights the need to reassess valuation assumptions for NBIX.

What did this article say?

Neurocrine Biosciences’ acquisition of Soleno Therapeutics added Vykat XR to its portfolio, but recent safety reports from the Foundation for Prader‑Willi Research highlight serious cardiac and respiratory events. Seven deaths and over 100 serious adverse events have been documented, prompting clinicians to monitor fluid retention and heart function closely. The drug’s launch in March 2025 has been followed by a 3% share decline, with an additional after‑hours slide after the safety warnings. The situation underscores the risk of post‑approval safety signals impacting market perception and regulatory scrutiny. Investors should watch for FDA safety reviews and any updates from the Foundation regarding patient monitoring protocols.

What did this article say?

Neurocrine Biosciences experienced a decline in share price following reports of safety concerns surrounding its Vykat XR therapy. The drug, approved for treating hyperphagia in Prader‑Willi syndrome, has been associated with serious adverse events, including cardiac complications. Market reaction reflects heightened scrutiny over post‑marketing safety data and potential regulatory actions. The company’s future performance may hinge on the resolution of these safety issues and the robustness of its risk mitigation strategies.

What did this article say?

Neurocrine Biosciences released findings from the KINECT-PRO™ study, demonstrating that INGREZZA® (valbenazine) capsules improve patient‑reported quality of life and daily functioning in individuals with tardive dyskinesia. The study’s results support the drug’s efficacy profile and may strengthen its positioning in the movement disorder market. Positive data could enhance market confidence and support future sales growth. The publication may also influence payer reimbursement decisions and clinical adoption rates. Investors should monitor the study’s impact on market perception and potential regulatory endorsements.

End of results